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Background: Acute kidney injury (AKI) severely worsens prognosis of hospitalized patients. Early Endothelial
Outgrowth Cells act protective in murine acute ischemic renal failure and renoprotective actions of eEOCs have
been documented to increase after cell pretreatment with 8-O-cAMP and Melatonin. Angiopoietin-1 is critically
involved in maintaining vascular integrity and regeneration. Aim of the study was to analyze the consequences of
eEOC treatment with Ang-1 in murine AKI.
Methods: After 40 minutes of unilateral renal artery clamping with contralateral nephrectomy, male C57/Bl6N mice
were injected with either untreated or pretreated (Ang-1) syngeneic murine eEOCs. Two days later serum creatinine
levels and morphology were evaluated. Cultured, Ang-1 treated murine eEOCs were analyzed for production/release
of proangiogenic and proinflammatory mediators, migratory activity, and cell survival, respectively.
Results: Angiopoietin-1 pretreatment of eEOCs significantly reduced serum creatinine in cell-injected mice. In vitro
analysis showed increased migration of Ang-1 treated eEOCs and supernatant from Ang-1 treated eEOCs stimulated
migration of cultured mature endothelial cells. In addition, Ang-1 reduced percentages of Annexin V+/PI+ eEOCs.
Intrarenal numbers of eEOCs remained unaffected by Ang-1 and eEOCs did not produce more or less
proangiogenic/proinflammatory mediators after being stimulated with Ang-1.
Conclusions: Angiopoietin-1 pretreatment of eEOCs increases the cells’ renoprotective competence in ischemic AKI.
Thus, the armentarium of eEOC agonists in AKI is increasingly being expanded and the treatment of AKI with eEOCs
becomes a promising future option.
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Acute renal failure (ARF) severely worsens prognosis
of hospitalized patients [1]. Approximately 1-5% of
all patients treated in the hospital develop ARF during
the course of the disease [2,3]. The most common
cause is prolonged hypoperfusion (acute ischemic kid-
ney injury – iAKI) [4]. A new therapeutic approach of
iAKI was identified in 2006. Goligorsky’s group showed* Correspondence: d.patschan@gmail.com
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reproduction in any medium, provided the orthat mice can be protected from iAKI by systemically
being injected with endothelial progenitor cells (EPCs) [5].
EPCs have been described for the first time in 1997 [6].
Since then, numerous studies evaluated the role of these
cells in vascular diseases [7-12]. Thus, it has widely been
accepted that the cells can serve as therapeutic tool in is-
chemic diseases such as ischemic heart, cerebrovascular,
and renal disease [5,13-15].
Since eEOCs (certain subpopulation of EPCs) have
been shown to protect the kidney from acute ischemic in-
jury, our major interest focused on strategies to increase
the cells’ renoprotective capacity in iAKI.al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vascular homeostasis [16]. Targeted gene inactivation stud-
ies showed that the early stages of vascular development
require VEGF whereas Angiopoietin-1 mediates vascular
remodeling during later stages [17]. Angiopoietin-2 in con-
trast can disrupt in vivo angiogenesis [18]. Both proteins
competetively interact with the endothelial-specific recep-
tor tyrosine kinase Tie-2 [19]. One fundamental biological
role of Angiopoietin-1 is to stabilize interendothelial cell
contacts. This results from Angiopoietin-1 induced de-
phosphorylation of PECAM-1 and VE-Cadherin, respect-
ively [20]. Endothelial cell migration, proliferation, and
differentiation on the other hand are also stimulated by the
protein [21]. Aim of the study was therefore to investigate
the effects of Angiopoietin-1 in the setting of an eEOC-
based therapy of iAKI.
Methods
Animal models
The animal study protocol was in accordance with the
guidelines of the German Institute of Health Guide for
the Care and Use of Laboratory Animals and approved
by the Institutional Animal Care and Use Committee.
C57BL/6 N mice were obtained from Jackson Labs (Bar
Harbor, ME, USA) and bred in the local animal facility
of the Göttingen University Hospital. All experiments
were performed with male 8–12 weeks old C57Bl/6 N
mice. All animals were caged separately with a 12:12-h
light–dark cycle and had free access to water and chow
throughout the study.
Surgical procedures
Mice were anesthetized (300 μl of 6 mg/100 g ketamine
hydrochloride plus 0.77 mg/100 g xylazine hydrochloride)
and placed on a heated surgical pad. Rectal temperature
was 37°C. After a 1.5-cm midlaparotomy, the left kidney
was exposed and clamping of the renal pedicle was
performed with microserrefines (Fine Science Tools,
Forster City, USA). Second, contralateral nephrectomy
was performed in order to induce ischemic AKI. The su-
ture placed around the right renale pedicle was held open
until cell injection. A certain volume of eEOC-containing
EBM-2 media (0.5 × 106 cells in 50 μl) was injected into
the right renal vein (systemic circulation). Very shortly
after cell injection, the suture was closed in order to pre-
vent bleeding. The kidney was removed afterwards. Thus,
the right kidney was removed before the contralateral
clamps were released. Clamping was performed for 40 mi-
nutes in all experiments. The vascular clamp was removed
about a minute before injecting eEOCs into the right renal
vein. The abdominal incision was closed with a 4–0 suture
and surgical staples. Two days (48 hours) after this pro-
cedure, animals were sacrificed and blood and kidney were
collected for further analysis. In each experimental group8–10 animals were analyzed. Previous own studies showed
that creatinine levels peak at 48 hours after unilateral IRI
post uni-nephrectomy [5].
Culture of mouse-derived early endothelial outgrowth
cells (eEOCs)
In order to perform cell injection experiments eEOCs
were isolated from C57Bl/6 N mice. Therefore, mouse
mononuclear cells (MNCs) were enriched by density
gradient centrifugation using Biocoll solution (Biochrom,
Berlin, Germany) from peripheral blood and spleen cell
extracts. The reason for pooling MNCs was to maximize
the total number of cells available for injection. Immedi-
ately following isolation, mononuclear cells were mixed
and 4 × 106 cells were plated in individual wells of a
24-well culture dish, coated with human fibronectin
(Sigma, St Louis, MO) and maintained in endothelial cell
medium-2 (EGM-2 - Clonetics, Lonza, Walkersville, MD,
USA) supplemented with endothelial growth medium
(EGM) Single-Quots containing 5% FCS. After 4–5 days of
culture, eEOCs were identified by the uptake of DiI-labeled
acetylated low density lipoprotein (acLDL) (Invitrogen,
Carlsbad, CA, USA) and binding of FITC-labeled BS-1 lec-
tin (BS-1) (Sigma Diagnostics, St. Louis, MO). For this pur-
pose, cells were first incubated with 10 μg/ml DiI-ac-LDL
at 37°C for 1 h and later fixed with 2% formaldehyde for
10 min, followed by incubation with BS-1 lectin at 37°C for
1 h. Cells that demonstrated double-positive immunofluor-
escence in laser scanning microscopy were defined as
eEOCs. Laser scanning microscopy was performed using
an inverted fluorescence microscope IX-71 (Olympus
Deutschland GmbH, Hamburg, Germany) equipped with
the appropriate excitation and emission filters (AHF
Analysentechnik, Tuebingen, Germany). Images of respect-
ive fluorescence channels were recorded as single high
resolution 16bit b/w images using a F-View II ext. Camera
(Olympus Deutschland GmbH, Hamburg, Germany). The
images from every fluorescence channel were then auto-
matically merged using the MFIP-module of the CELL-F®
software. In some experiments cells that were used for
injection experiments were not labelled with acLDL
and BS-1 lectin, but were incubated with CellTracker®
(Molecular Probes, Eugene, OR, USA) according to the
manufacturer’s protocol.
In vitro treatment of eEOCs before therapeutic
administration
Early Endothelial Outgrowth Cells employed for sys-
temic injections were detached by trypsinization after
the first passage, and, after neutralization of trypsin, in-
cubated with CellTracker®. After washing the cells once
with PBS, they were resuspended in 50 μl of EGM-2 for
systemic injection or for further in vitro treatment. For
in vitro treatment eEOCs were incubated with Ang-1
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therapeutics, San Pedro, CA, USA) for 60 minutes at 37°C.
After washing the cells once with EGM-2, they were
resuspended in 50 μl of EGM-2 for systemic injection.
Immunofluorescence microscopy
Tissue samples were fixed in a 4% formaldehyde solution
for one hour, followed by incubation in 30% sucrose over-
night at 4°C. Embedding was performed in an OCT com-
pound (Tissue-Tek, Torrance, CA, USA), and embeddedA
B
C.1
Figure 1 Cultured murine eEOCs and renal function after cell therapy. A
blue: nuclei, magnification × 100). Eighty-six ± 3.7% of all cultured cells showed
Administration of untreated eEOCs did not improve renal function but injectio
compared to mice without cell therapy and to mice with administration of un
kidneys of cell-injected mice. Since previous investigations showed eEOC accum
the borderzone between medulla and papilla. Nevertheless, cell were de fa
cells – C.2) (magnification in C × 40, IRI: ischemia reperfusion injury, Data assamples were stored at −20°C. Frozen samples were cut
into 10 μm thick sections. Non-specific protein binding
was blocked by 1 hour incubation with PBS-BSA (1%). Sec-
tions were incubated with FITC-conjugated anti-mouse
CD117 (c-Kit, 1:1000 in PBS-BSA 1%) (BD Biosciences,
Rockville, MD, USA) or with the respective isotype control
for 12 hours at 4°C. To visualize the nuclei, tissue sections
were counterstained with DAPI (1:200 in PBS) (Molecular
Probes, Eugene, OR, USA). Sections were examined as pre-
viously described.C.2
depicts BS 1+/acLDL+ cells (eEOCs) (green: BS 1 lectin-FITC, red: acLDL-Dil,
double-positive staining. B shows renal function of cell injected animals.
n of Ang-1 pretreated cells significantly improved renal function as
treated eEOCs. C (C.1 and C.2) shows immunofluorescence images from
ulation in the medullo-papillary area, our particular interest focused on
cto absent in both groups (untreated cells – C.1 and Ang-1 pretreated
mean ± SEM, *: p < 0.05).
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Serum creatinine concentration was measured using a
commercially available kit (Creatinin PAP, Labor und
Technik - Eberhard Lehmann, Berlin, Germany) according
to the manufacturer’s protocol.
Cell migration assays
The eEOC cell migration assay was performed as pub-
lished by Shi et al. [22]. Briefly, cells were grown on fibro-
nectin coated 6 well plates. As soon as the well area was
completely covered by cells (after approx. 5–6 days), an
artificial wound was created, using the tip of a syringe.
Cells remained in either Angiopoietin-1 free EBM-2 or
in Ang-1 containing medium (250 ng/ml). Incubation
time was one hour in every series of experiments. Each
series was performed three times. After cell washing with
Ang-1 free EBM-2, images of the respective wound areas
were taken at 0 and 24 hours. Commercially available
human umbilical vein endothelial cells (HUVECs – PCS-
100-013, ATTC, Wesel, Germany) were cultured on fi-
bronectin coated 6 well plates in EBM-2. An artifical
wound was created as described. Cells were incubatedFigure 2 Effects of Ang-1 on migratory activity of cultured eEOCs (A) an
medium from Ang-1 treated eEOCs. Ang-1 induced faster direct and indirect w
wound healing assay with C – Control; B: wound area reduction after 24 hours
reduction after 27 hours). Number of analysis in each group: 6, Data as mean ±with supernatant EBM-2 from eEOCs that were incu-
bated with Ang-1 for one hour. After incubation, super-
natant was removed and cells remained in fresh EBM-2
for one more hour. Supernatant was then used for treat-
ment of HUVECs. Incubation time with supernatant was
3 hours. Images of the respective wound areas were taken
at 3 and 27 hours. The experiment was performed at
least three times.
ELISA studies
For all in vitro cell experiments, a commercially available
murine ’early outgrowth’ endothelial progenitor cell line
was purchased (66110–37 - Celprogen stem cell research
and therapeutics, San Pedro, CA, USA). Cells were cul-
tured according to the manufacturer’s protocol. Cell
treatment with Ang-1 was performed as described above.
For measuring levels of Vascular Endothelial Growth Fac-
tor, Insulin-like Growth Factor-1, Interleukin-6, and
Transforming Growth Factor-β in the culture medium at
24 hours after cell treatment, commercially available
ELISA tests were performed according to the manufac-
turer’s protocol (R&D Systems, Minneapolis, MN, USA).d cultured mature endothelial cells (C). The latter were incubated with
ound closing, indicating proendothelial effects of the protein (A: direct
; C: indirect wound healing assay with C – Control, D: wound area
SEM, *: p < 0.05).
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ney samples were thawed and frozen for 3 times in PBS.
After the last cycle, tissue homogenates were centrifuged
at 5.000 g and supernatants were employed for ELISA
studies.
Analysis of eEOC apoptosis and necrosis
For analyzing the effects of Ang-1 on eEOC apoptosis
and necrosis, cultured murine eEOCs were incubated
with either medium alone or with Ang-1 containing
medium (250 ng/ml). As reported earlier [23], apoptosis/
necrosis was induced by treating the cells with TGF-β.
Cells were first incubated with TGF-β (TGF-β 5 ng/ml), in
some experiments Ang-1 (250 ng/ml) was added after a
period of 2 hours, both mediators remained in the culture
medium for one more hour. Either untreated or pretreated
cells (TGF-β alone, TGF-β/Ang-1 combined) were washed
and 24 hours later apoptosis and necrosis were evaluated.
For analyzing apoptosis, the percentage of Annexin V +
cells was quantified using a commercially available kit
(BD, Heidelberg, Deutschland) according to the manufac-
turer’s protocol. Necrosis was measured by cytometric ana-
lysis. Briefly, cells with positive uptake of propidium iodide
were defined as necrotic.
Statistical analysis
The results were expressed as mean ± SEM. The means
of two populations were compared by Student’s t testFigure 3 Analysis of eEOC release of VEGF (A), IGF-1 (B), and TGF-β (C
eEOCs (Data as mean ± SEM).(unpaired with equal variance). Differences between three
or more groups were compared by ANOVA one way ana-
lysis of variance. Differences were considered significant at
p < 0.05.
Results
Angiopoietin-1 increases renoprotective competence
of eEOCs in iAKI
After a 40 minutes period of ischemia mice were intra-
venously injected with 0.5 × 106 Ang-1 pretreated cells.
Serum creatinine levels of cell injected animals signifi-
cantly improved as compared to postischemic mice that
did not receive any cells at all or that received un-
treated cells (0.15 ± 0.01 mg/dl vs. 0.22 ± 0.03 mg/dl or vs.
0.19 ± 0.004 mg/dl, p = 0.009 and p = 0.02 – Figure 1).
Angiopoietin-1 does neither increase nor decrease
postischemic eEOC homing
In order to analyze postischemic cell homing, some exper-
iments required eEOC labelling with cell tracker® solution
(CM-Dil). Cell tracker® incubation of eEOCs was exclu-
sively performed for analyzing cell homing since prelimin-
ary experiments using Ang-1 pretreated cells showed that
renal function can deteriorate after labelling the cells (data
not shown). Immunofluorescence analysis showed de facto
no cell infiltrates in all injected animals as it has been
reported in previous studies [5,23,24]. Representative im-













































Figure 4 Apoptosis and necrosis of Ang-1 treated eEOCs.
Percentages of Annexin V+/PI+ (double-positive) cells were significantly
lower in Ang-1 incubated cells as compared to untreated eEOCs (A).
B shows percentages of Annexin V+/PI- cells. Percentages did not differ
bewteen the groups which indicated that differences in double-positive
cells were the result of increased necrosis rather than apoptosis (Data as
mean ± SEM, *: p < 0.05).
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eEOCs
We next aimed to determine the migratory activity of
cultured eEOCs in the presence of Ang-1. Angiopoietin-
1 significantly accelerated wound closing as indicated by
smaller wound areas at 24 hours after treatment (69 ± 8%
wound closing vs. 32 ± 22% wound closing, p = 0.03,
Figure 2).
Angiopoietin-1 stimulates migration of cultured human
endothelial cells in an indirect manner
After artificial wound induction, human umbilical vein
endothelial cells were incubated with medium from
Ang-1 treated eEOCs. This measure significantly acceler-
ated wound closing (92 ± 8% wound closing vs. 30 ± 6%
wound closing, p = 0.0005, Figure 2), indicating that
Angiopoietin-1 treatment of eEOCs increases indirect
proangiogenic effects of the cells.
Angiopoietin-1 does not increase eEOC release of
proangiogenic or inflammatory mediators
We next evaluated eEOC production/secretion of different
proangiogenic and proinflammatory mediators. Twenty-
four hours after a one hour period of Ang-1 treatment,
concentrations of vascular endothelial growth factor
(VEGF), Insulin-like Growth Factor-1 (IGF-1), Interleukin-
6 (IL-6), and Transforming Growth Factor-β (TGF-β) were
not different in the supernatants from untreated as com-
pared to Ang-1 treated eEOCs (Figure 3). Results of IL-6
measurements are not part of Figure 3 since the cytokine
was almost not detectable at all in supernatant from
untreated/treated cells.
Angiopoietin-1 reduces apoptosis/necrosis of eEOCs
Finally, we evaluated whether Angiopoietin-1 modu-
lates TGF-β induced apoptosis/necrosis of cultured mur-
ine eEOCs. Twenty-four hours after a one hour period
of Angiopoietin-1 treatment, eEOC were analyzed for
Annexin V expression and propidiumiodide uptake.
Angiopoietin-1 significantly reduced percentages of
double-positive cells (6.8 ± 1.1% vs. 11.6 ± 1.9%,
p = 0.0004 – Figure 4). In fact both processes of cell dam-
age (apoptosis and necrosis) were reduced in the presence
of Ang-1 but necrosis, as represented by uptake of PI was
decreased to an even greater extent. Thus, the Annexin
V/PI ratio was diminished as well.
Discussion
Early Endothelial Outgrowth Cells significantly protect
mice from acute ischemic renal failure. This has mean-
while been proven in a number of different experimental
studies [5,23-26]. In attempting to establish the cells as
future therapeutic tool in ischemic AKI, different strategies
have been identified, helpful to increase renoprotectiveeffects of eEOCs. In 2010, 8-O-cAMP was identified as
eEOC agonist, inducing redistribution of integrin mole-
cules towards the plasma membrane of the cells thereby
enhancing postischemic cell homing [24]. The hormone
melatonin improved antiischemic actions of eEOCs in AKI
as well [23]. Recently, the protein BMP-5 was identified as
another eEOC agonist in this situation [27]. Thus, Early
Endothelial Outgrowth Cells increasingly become a thera-
peutic option in ischemic AKI.
Aim of the current study was to analyze consequences
of Angiopoietin-1 (Ang-1) treatment of eEOCs in the
context of eEOC-mediated postischemic kidney repair.
Pretreatment of the cells resulted in significant lower
concentrations of serum creatinine in cell-injected mice,
which was accompanied by higher resistance of cultured
eEOCs against TGF-β induced apoptosis/necrosis and by
increased cell migration. In addition, supernatant from
Ang-1 incubated eEOCs markedly enhanced migratory ac-
tivity of cultured mature endothelial cells. Postischemic
cell homing or production/secretion of proangiogenic me-
diators remained unaffected by Ang-1. The latter findings
Patschan et al. BMC Nephrology 2013, 14:227 Page 7 of 8
http://www.biomedcentral.com/1471-2369/14/227are somehow surprising, regarding the fact that eEOCs
predominantely act through secreted signals. The cells
home into the interstitial space of postischemic tissues
where they release proangiogenic mediators in a paracrinic
manner [28]. Miscellaneous substances have been identi-
fied in the past, including VEGF, HGF, IGF-1 [28,29],
matrix metalloproteinase 9, IL-8, and others [30,31]. Al-
though VEGF plays a fundamental role in orchestrating
protective effects of the cells [23,28], we did not find in-
creased cellular secretion of VEGF (and HGF). An alterna-
tive mechanism of EPC(eEOC)-mediated vasoprotection
has lately been introduced by the group of Goligorsky
[32]. Yasuda and colleagues showed direct interaction be-
tween EPCs and mature endothelial cells by the generation
of so-called nanotubes, cell membrane-build structures
which allow direct transfer of lysosome constituents and
other molecules from one cell to the other [32]. This study
indicated the potential relevance of direct cell-cell commu-
nication, in addition to indirect paracrinic EPC effects.
However, our investigation did [5,23,24] not reveal any
relevant cell incorporation into the postischemic endothe-
lium or any accumulation of eEOCs in close proxomity to
endothelial cells. This is by the way in line with the cur-
rently favored concept of eEOC-mediated vasorepair
[26,30]. The virtual absence of eEOCs in the postischemic
kidney at 48 hours has been reported in previous eEOC/
AKI-related studies [23,33] and comparable data has been
documented for mesenchymal stem cells as well [34]. So
far, significant and increased postischemic eEOC homing
has only been observed in one of our studies. The sub-
stance 8-O-cAMP induced redistribution of β1-integrin
molecules towards the plasma membrane of eEOCs
resulting in increased transvascular cell migration into
the interstitial space [24]. Nevertheless, our analyses of
postischemic kidneys were performed 48 hours after ische-
mia. Severe ischemia-related endothelial dysfunction typic-
ally occurs within the first 24 hours and the absence of
injecetd cells at the end of day two only supports the con-
cept of (transient) paracrinic cell actions of eEOCs [35].
Angiopoietin-1 plays a crucial role in maintaining vascular
homeostasis under physiological conditions and this study
undoubtedly proves an eEOC-agonistic role of the protein
in iAKi although it still remains to be elucidated which
excact mechanisms promote eEOC renoprotection in vivo.
At this point, several endogenous [25] and exogenous
agonists of eEOCs have been identified (8-O-cAMP,
Melatonin, BMP-5, Ang-1 [23,24,27]). A first study on
therapeutic administration of eEOCs in human AKI is be-
ing planned at the moment. Thus, exogenous measures,
helpful to improve renoprotective competence of the cells
in ischemic AKI are needed. Another important question
with regard to an EPC-based therapy of ischemic AKI is
related to the mid- to long-term outcome of cell treated
animals/patients. It has to be analyzed whether EPCsdiminish postischemic vascular rarefication/interstitial fi-
brosis, two events which substantially worsen prognosis of
patients in the long-term.
In summary, Angiopoietin-1 has been identified as po-
tent agonist of syngeneic murine eEOCs in ischemic AKI.
The protein increases renoprotective effects of the cells
in vivo and activates cultured cells on different levels.
Angiopoietin-1 is therefore a promising tool for stimulat-
ing eEOC-mediated renoprotection in ischemic AKI.
Conclusions
In conclusion, Angiopoietin-1 has been identified as new
agonist of murine eEOCs in ischemic AKI. The sub-
stance does not increase postischemic cellular homing
into the kidney but significantly promotes cellular activ-
ity as reflected by increased survival and migration. In
addition, Ang-1 treated eEOCs stimulate competence of
mature endothelial cells through secreted signals. Thus,
the protein will potentially serve as candidate for prim-
ing eEOCs in an eEOC-based therapeutic regimen of
AKI.
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